In mid-October, Guo Guangchang, founder of Fosun, flew to Mumbai in his private plane to attend the dinner celebrating the Chinese conglomerate’s purchase of Indian pharma company Gland. For many weeks, approval for the transaction had been held up — hostage to the border dispute between India and China in Doklam. The situation was finally resolved not because Delhi signed off but because Gland’s founder, PVN Raju, agreed to sell a smaller portion of his holdings, bringing the transfer below the 74 per cent threshold that triggered the need to secure the government’s blessing. Over mao-tai, (which the Fosun people claimed cost $1,000 a bottle), Mr Guo, clad in jeans and a T-shirt, said he hoped to do many more deals in India, according to several attendees. Fosun has already joined the many Chinese companies backing tech start-ups in the country.
10月中旬，复星集团(Fosun)创始人郭广昌乘坐自己的私人飞机前往孟买出席这家manbetx3.0 综合企业收购印度制药商Gland的庆祝晚宴。受制于印中两国在多兰（Doklam，manbetx3.0 称洞朗——译者注）的边境争端，该交易在好几周期间迟迟未能获得批准。这一局面最终得以解决，并不是因为新德里方面放行，而是因为Gland的创始人PVN Raju同意出售较少股份，使得股权转让份额低于74%的门槛——超过这一门槛的交易必须获得印度政府批准。据一些参加晚宴的人介绍，身着牛仔裤和T恤衫的郭广昌举着装着茅台（复星员工称一瓶茅台的价格为1000美元）的酒杯说，他希望在印度做成更多交易。复星已经加入了支持印度科技初创企业的manbetx3.0 企业大军。